Ownership and insider activity for Supernus Pharmaceuticals, Inc. (SUPN): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention.
Price
| Price | $43.04 |
| Market Cap | $2.5B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-12 | Khattar Jack A. | M-Exempt | 29,849 | |
| 2026-08-12 | Khattar Jack A. | F-InKind | 12,642 | $589K |
| 2026-08-12 | Khattar Jack A. | M-Exempt | 29,849 | |
| 2026-08-12 | Rubin Jonathan | M-Exempt | 750 | |
| 2026-08-12 | Rubin Jonathan | F-InKind | 363 | $17K |
| 2026-08-12 | Rubin Jonathan | M-Exempt | 750 | |
| 2026-08-12 | Bhatt Padmanabh P. | M-Exempt | 2,500 | |
| 2026-08-12 | Bhatt Padmanabh P. | F-InKind | 1,158 | $54K |
| 2026-08-12 | Bhatt Padmanabh P. | M-Exempt | 2,500 | |
| 2026-08-12 | Mottola Frank | M-Exempt | 1,650 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $90.1M | $100.3M | $192.2M | $181.4M | $288.6M | $203.4M | $93.1M | $75.1M | $69.3M | $128.4M |
| Short-term Investments | 0 | $39.7M | $163.8M | $165.7M | $133.9M | $136.2M | $368.2M | $179.8M | $384.3M | $180.2M |
| Receivables | $41.5M | $65.6M | $102.9M | $87.3M | $140.9M | $148.9M | $165.5M | $144.2M | $142.1M | $187.8M |
| Inventory | $16.8M | $16.3M | $25.7M | $26.6M | $48.3M | $86.0M | $91.5M | $77.4M | $54.3M | $82.4M |
| Total Current Assets | $151.4M | $228.5M | $493.5M | $472.6M | $630.4M | $601.6M | $734.2M | $493.1M | $686.1M | $644.2M |
| Property, Plant & Equipment | $4.3M | $5.1M | $4.1M | $17.1M | $37.8M | $17.0M | $15.2M | $13.5M | $11.5M | $10.5M |
| Goodwill | 0 | 0 | 0 | 0 | $77.9M | $117.5M | $117.0M | $117.0M | $117.0M | $124.9M |
| Intangible Assets | $16.5M | $36.0M | $31.4M | $24.8M | $364.3M | $784.7M | $702.5M | $599.9M | $521.9M | $569.5M |
| Total Assets | $309.6M | $424.5M | $977.8M | $1.16B | $1.50B | $1.69B | $1.70B | $1.28B | $1.37B | $1.45B |
| Accounts Payable | $8.1M | $6.8M | $3.2M | $10.1M | $6.1M | $9.3M | $10.5M | $2.0M | $4.6M | $2.7M |
| Short-term Debt | 0 | $4.3M | $2.2M | 0 | 0 | 0 | $402.0M | 0 | 0 | 0 |
| Total Current Liabilities | $80.7M | $123.0M | $161.4M | $160.6M | $245.1M | $315.4M | $688.0M | $290.2M | $292.4M | $338.2M |
| Long-term Debt | $4.2M | $22.3M | $329.5M | $345.2M | $361.8M | $379.3M | 0 | 0 | 0 | 0 |
| Total Liabilities | $117.8M | $157.0M | $524.8M | $564.9M | $759.2M | $873.3M | $816.3M | $356.2M | $332.3M | $390.9M |
| Retained Earnings | -$84.3M | -$26.8M | $86.5M | $199.5M | $326.5M | $379.9M | $481.2M | $482.6M | $556.4M | $517.9M |
| Total Equity | $191.8M | $267.5M | $453.0M | $595.4M | $744.9M | $815.9M | $886.2M | $921.5M | $1.04B | $1.06B |
| Total Debt | $4.2M | $26.5M | $329.5M | $378.4M | $414.3M | $427.0M | $444.8M | $41.5M | $34.3M | $41.0M |
| Net Debt | -$86.0M | -$113.5M | -$26.6M | $31.4M | -$8.2M | $87.3M | -$16.6M | -$213.3M | -$419.3M | -$267.7M |
| Working Capital | $70.7M | $105.5M | $332.1M | $312.1M | $385.3M | $286.2M | $46.2M | $202.9M | $393.7M | $306.0M |
Financial Health
| Debt / Equity | 0.04 |
| Current Ratio | 2.08 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 5.47 |
Profitability
| Return on Equity | -10.42% |
| Return on Invested Capital | -9.12% |
| Return on Assets | -7.69% |
| Gross Margin | 88.07% |
| Operating Margin | -13.46% |
| Net Margin | -13.23% |
Related companies: AMRX · BHC · CGON · GRAL · HCM · INDV
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of SUPN: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks